Vanguard reports 4.92% stake in Emergent BioSolutions
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 2,540,945 shares of Emergent BioSolutions Inc. common stock, representing 4.92% of the class as of June 30, 2026.
Rhea-AI Filing Summary
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 2,540,945 shares of Emergent BioSolutions Inc. common stock, representing 4.92% of the class as of June 30, 2026. Vanguard has sole voting power over 342,106 shares and sole dispositive power over all 2,540,945 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard funds and managed accounts over which these entities exercise voting and/or dispositive authority, and no other single person’s interest in these securities exceeds 5%.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole dispositive power financial
sole voting power financial
percent of class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Emergent BioSolutions (EBS) does Vanguard report in this Schedule 13G/A?
What dispositive power does Vanguard report over its Emergent BioSolutions (EBS) holdings?
Why does the Schedule 13G/A for Emergent BioSolutions (EBS) note ownership of 5 percent or less?
Do other parties have rights to dividends or sale proceeds from Vanguard’s Emergent BioSolutions (EBS) shares?
Which Vanguard affiliates are included in the Emergent BioSolutions (EBS) beneficial ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.